Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
[Intrathecal immunoglobulin production in the diagnosis and differential diagnosis of multiple sclerosis.]
An early British case of neuromyelitis optica (1850).
Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial.
Botulinum Toxin-What Urologic Uses Does the Data Support?
Multiple sclerosis in New Zealand.
Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis.
The RESTORE trial: What did we learn about multiple sclerosis?
Reduced spontaneous sympathetic nerve activity in multiple sclerosis patients.
Lead Candidate (MIS416) Overview
Aquaporin-4 autoimmunity.
[Pegylated interferon beta 1a : A new therapy option for treatment of relapsing-remitting multiple sclerosis].
Abnormally high levels of anti-collagen type IV IgG antibodies in the serum of patients with a clinically isolated syndrome correlate with an increased risk of conversion to MS.
Chronic cerebrospinal venous insufficiency: pitfalls and perils of sonographic assessment.
Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis.
White and gray matter damage in primary progressive MS: The chicken or the egg?
Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping.
Preliminary validation study of the Spanish version of the satisfaction with life scale in persons with multiple sclerosis.
Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.
Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal model of multiple sclerosis.
Genetic inactivation of PERK signaling in mouse oligodendrocytes: Normal developmental myelination with increased susceptibility to inflammatory demyelination.
Lessons learned from studies of natural resistance in murine experimental autoimmune encephalomyelitis.
Towards a Quantitative OCT Image Analysis.
Relevance of CD34+ Cells as a Reservoir for JC Virus in Patients With Multiple Sclerosis-Reply.
The role of neurotrophins in multiple sclerosis-pathological and clinical implications.
Pages
« first
‹ previous
…
466
467
468
469
470
471
472
473
474
…
next ›
last »